The research, led by Faiz Qamar under the supervision of Manju Sharma, focused on a well-established animal model of type 2 diabetes. Female Wistar rats were first fed a high-fat diet and then given a single intraperitoneal dose of streptozotocin at 35 milligrams per kilogram, a protocol that reproduces the insulin resistance and pancreatic beta-cell dysfunction characteristic of human type 2 diabetes. Once diabetes was established, the animals were divided into treatment groups receiving oral therapy for twelve weeks: canagliflozin alone at either 10 or 20 milligrams per kilogram, fenugreek seed extract at 400 milligrams per kilogram, canagliflozin at 10 milligrams per kilogram combined with metformin at 200 milligrams per kilogram, or the full triple combination of canagliflozin, metformin, and fenugreek seed extract at the same doses.

What makes this study technically significant is the breadth of skeletal endpoints the investigators measured. At the end of the treatment period, they assessed serum insulin and glycated haemoglobin, or HbA1c, as markers of long-term glycaemic control. For bone health, they turned to tartrate-resistant acid phosphatase, or TRAP, a serum enzyme released by osteoclasts, the cells responsible for breaking down bone. Elevated TRAP activity signals accelerated bone resorption. They also measured urinary calcium excretion, an indicator of calcium loss from the skeleton, and used micro-computed tomography, or micro-CT, to visualize and quantify the three-dimensional trabecular architecture of the femur, the spongy internal scaffolding that gives bone its strength while remaining light.

The untreated diabetic animals showed exactly the pattern of deterioration that clinicians fear in patients with long-standing diabetes. Their femoral trabecular bone exhibited marked reductions in bone volume fraction, trabecular thickness, trabecular number, and connectivity density, the last being a measure of how well the internal struts of bone are connected to one another and therefore how effectively the structure distributes mechanical load. At the same time, trabecular separation, the average gap between bone struts, increased, as did the structural model index, or SMI, a parameter that shifts toward plate-like and rod-like geometry as bone becomes weaker and more fracture-prone. Histological examination of the bone tissue confirmed these micro-CT findings, painting a consistent picture of diabetes-driven skeletal fragility.

Against this backdrop, the treatment results were striking. By week twelve, the triple combination of canagliflozin, metformin, and fenugreek seed extract had reduced fasting blood glucose by approximately 57.8 percent compared with diabetic control animals, while HbA1c fell by roughly 47.4 percent. These are substantial metabolic improvements, but the skeletal data were equally compelling. Serum TRAP activity, the biochemical signature of osteoclast-driven bone breakdown, declined by about 26.1 percent in the combination group, and urinary calcium excretion dropped by approximately 31.4 percent, suggesting that less calcium was being leached from the skeleton and lost through the kidneys.

Canagliflozin itself deserves particular attention in this context. The drug belongs to the sodium-glucose co-transporter 2, or SGLT2, inhibitor class, which works by blocking glucose reabsorption in the proximal tubule of the kidney, forcing excess glucose to be excreted in the urine. While the class has proven cardiovascular and renal benefits, some clinical evidence, including analyses from the CANVAS trial program, has raised questions about fracture risk with canagliflozin, making its skeletal profile a subject of genuine scientific debate. The new findings suggest that, at least in this experimental model of diabetic osteopathy, canagliflozin-based regimens attenuated rather than worsened trabecular deterioration, a result the authors argue supports further investigation of the drug’s skeletal effects and the mechanisms underlying them.

Metformin, the second pharmaceutical component of the combination, brings a different mechanism to the table. It acts primarily through activation of AMP-activated protein kinase, or AMPK, a cellular energy sensor that influences glucose production in the liver and insulin sensitivity in peripheral tissues. Interestingly, metformin has also been implicated in bone biology, with studies suggesting it may modulate the balance between osteoblasts, the bone-forming cells, and osteoclasts, the bone-resorbing cells. By improving insulin signalling, metformin may indirectly support bone, since insulin itself has anabolic effects on the skeleton, stimulating osteoblast activity and bone formation. The interplay between glycaemic control and bone metabolism is therefore not merely coincidental but mechanistically intertwined.

The third ingredient, fenugreek seed extract, is derived from Trigonella foenum-graecum, an herb with a long history in traditional medicine systems across South Asia and the Middle East. Modern research has identified multiple bioactive compounds in fenugreek, including the steroidal saponin diosgenin, which has been shown in cell studies to influence the Wnt/beta-catenin signalling pathway, a key regulator of osteoblast proliferation and differentiation. Fenugreek has also demonstrated antidiabetic properties in numerous preclinical and some clinical studies, thought to arise from its fibre content, saponins, and 4-hydroxyisoleucine, an amino acid with insulin-sensitizing activity. Including a botanical extract alongside two established pharmaceuticals reflects a growing interest in adjunctive phytotherapy for metabolic disease, though the authors are careful to frame the results as preclinical evidence requiring further study rather than a prescription for human use.

The significance of the study lies partly in its systematic comparison of monotherapy and combination approaches. Canagliflozin alone, at both doses tested, along with fenugreek seed extract and the dual canagliflozin-metformin combination, all attenuated the diabetes-associated skeletal alterations to varying degrees, but the triple regimen produced the most pronounced improvements in both metabolic and microarchitectural parameters. This dose-response-like gradient across regimens hints at possible additive or synergistic effects among the three agents, whether through complementary mechanisms of glucose lowering, reduced glucotoxicity in bone cells, or direct effects on osteoblast and osteoclast activity. The consistency between the biochemical markers, the micro-CT quantification, and the histological observations strengthens the internal validity of the findings, since each independent line of evidence points in the same direction.

For the millions of people living with type 2 diabetes, the spectre of skeletal fragility is an underappreciated burden. Diabetic bone disease differs from ordinary osteoporosis in that bone mineral density may appear normal or even elevated on standard scans, yet fracture risk remains substantially increased, a paradox attributed to impaired bone quality, accumulation of advanced glycation end-products that stiffen the collagen matrix, and disrupted remodelling. The Jamia Hamdard team’s work adds an important piece to this puzzle by demonstrating that aggressive glycaemic management with a rational drug combination can preserve trabecular microarchitecture in a model that closely mimics the human disease. While the results must be replicated and extended, including studies of bone strength and fracture mechanics, and ultimately clinical trials in patients, the message is clear: the drugs we choose to control diabetes may also shape the skeleton, and the right combinations could turn that influence to the patient’s advantage. The study was approved by the Institutional Animal Ethics Committee at Jamia Hamdard and conducted in compliance with Indian regulatory guidelines, with the authors reporting no conflicts of interest.

Subject of Research: Effects of canagliflozin, metformin, and fenugreek seed extract combinations on bone health in experimental diabetes

Article Title: Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy

Article References: Qamar, F., Sultana, S., Vaseem, M., Ahmad, T., & Sharma, M. (2026). Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy. 3 Biotech, 16(10), Article 446. https://doi.org/10.1007/s13205-026-05079-1

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05079-1

Keywords: diabetes, diabetic osteopathy, canagliflozin, metformin, fenugreek seed extract, SGLT2 inhibitors, bone microarchitecture, micro-CT, trabecular bone, streptozotocin, rat model, HbA1c

The research team, led by W. Aidan Martel, S. Bradley King, and senior author Rebecca V. Mountain, set out to answer two questions that previous work had left open. First, do the sex differences seen in isolation-induced bone loss simply reflect different timelines, with females eventually succumbing to the same damage if given enough time? Second, what role do the sex steroid hormones estrogen and testosterone play in mediating the skeletal response? To address these questions, the investigators housed 16-week-old C57BL/6J mice either in groups of four per cage or alone, one mouse per cage, for periods of 2, 4, or 8 weeks, and then subjected their bones to detailed structural, biomechanical, and molecular analysis.

The results were unambiguous for the males. Single housing significantly reduced bone parameters across every treatment length tested. On average, isolated male mice showed a 20 percent reduction in trabecular bone volume fraction, a key measure of the spongy, metabolically active bone found inside the ends of long bones and vertebrae. Cortical thickness, the measure of the dense outer shell of bone that provides most of a skeleton’s resistance to bending and fracture, fell by an average of 8 percent. Critically, these changes appeared remarkably fast: trabecular bone was measurably affected after as little as two weeks of isolation, suggesting that the male skeleton responds to the loss of social contact with surprising speed.

Structure alone does not determine whether a bone will break, so the team also tested mechanical performance. Bones are not simply mineral scaffolds; their ability to absorb energy and resist fracture depends on the interplay of material quality and architecture. When the researchers subjected the femurs to biomechanical testing, they found that isolation degraded the mechanical properties of the bone in male mice but not in females. In practical terms, the isolated males were left with femurs that were thinner, less dense, and weaker, a combination that in a living animal would translate into a substantially elevated fracture risk.

The females told a very different story. Across all three treatment durations, the overall bone phenotype of isolated female mice was essentially unaffected. Trabecular and cortical parameters held steady, and biomechanical performance remained comparable to that of group-housed controls, even after eight weeks of single housing. This finding rules out the simplest explanation for the sexual dimorphism, namely that females merely respond more slowly. Whatever protects the female skeleton from the consequences of social isolation, it is not a matter of delayed onset but of a fundamentally different biological response.

Yet the female skeleton was not entirely silent. When the researchers measured bone turnover markers, the biochemical signals of bone formation and bone resorption that circulate in the blood, they found that isolated females showed an increase after just two weeks of isolation. Bone remodeling is a continuous process in which osteoclasts break down old bone and osteoblasts lay down new bone, and shifts in turnover markers indicate that the cellular machinery had been perturbed even though the net structure remained intact. The authors interpret this as evidence that isolated females experienced changes in bone remodeling dynamics that somehow resolved without producing measurable bone loss, a decoupling that may itself hold clues to the protective mechanism.

The search for a hormonal explanation produced one of the study’s most intriguing results. In male mice isolated for four or eight weeks, the researchers observed alterations in the expression of estrogen-related genes, even though circulating estrogen levels themselves were unchanged. This dissociation between gene expression and circulating hormone concentration suggests that the skeletal response to isolation may be mediated locally, at the level of the bone tissue itself, rather than through systemic changes in sex steroid availability. It also raises the possibility that estrogen signaling, traditionally studied in the context of female physiology, plays an underappreciated role in the male skeleton’s response to psychological stress.

The clinical resonance of these findings is considerable. Social isolation and loneliness affect a large and growing share of the human population, particularly older adults, and epidemiological studies have associated them with elevated risks of numerous chronic conditions. If a sexually dimorphic relationship between social contact and bone health exists in humans, as the murine data suggest it might, then men who are socially isolated could represent an unrecognized population at elevated risk of osteoporosis and fragility fracture. Osteoporosis is already underdiagnosed in men, in part because the disease is often perceived as a condition of postmenopausal women, and a psychosocial contribution to male bone loss could sharpen both screening and prevention strategies.

The study also sounds a cautionary note for the research community. Single housing is a routine practice in biomedical research, whether for experimental necessity, behavioral phenotyping, or animal management, and the new data show that this housing condition is not physiologically neutral, at least for male rodents. Any study using individually housed male mice as a baseline could be inadvertently measuring the skeletal consequences of isolation superimposed on the experimental variable of interest. The authors note that these findings have important implications for pre-clinical rodent models utilizing single housing, and the rapid two-week onset of bone changes suggests that even short housing periods may be sufficient to confound skeletal endpoints.

Many questions remain. The precise mechanism linking social isolation to osteoclast and osteoblast activity is still unknown, as is the identity of the factor that shields female bone. The role of testosterone, which the study set out to examine, and the functional significance of the altered estrogen-related gene expression in males, will require further investigation. What is already clear, however, is that the skeleton listens to the social environment, and that it does so differently in males and females. As loneliness becomes an increasingly prominent public health concern, this work suggests that its costs may be written not only in the brain and the heart, but in the very architecture of bone, and that sex must be part of any equation that seeks to predict who pays the price.

Subject of Research: Sex-dependent effects of social isolation on bone health in adult mice

Article Title: Short- and long-term effects of social isolation on adult murine bone are sex-dependent

Article References: Martel, W. A., King, S. B., Buchanan, E., Merrill, B. M., Stohn, J. P., Brooks, D. J., Barlow, D., Motyl, K. J., & Mountain, R. V. (2026). Short- and long-term effects of social isolation on adult murine bone are sex-dependent. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00995-6

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00995-6

Keywords: social isolation, bone health, sexual dimorphism, osteoporosis, trabecular bone, cortical bone, bone turnover, estrogen, testosterone, murine model, loneliness, biomechanics